|
See related Alkeran tab information |
|
|
|
Manufacturer |
Invida |
|
Distributor |
Zuellig |
|
Contents |
Melphalan |
|
Indications |
Multiple myeloma, advanced ovarian adenocarcinoma, carcinoma of breast, polycythaemia rubra vera. |
|
Dosage |
Adult Multiple myeloma 0.15 mg/kg body wt/day in divided doses for 4 days repeated at intervals of 6 wk. Advanced ovarian adenocarcinoma 0.2 mg/kg body wt/day orally for 5 days, repeated every 4-8 wk. Carcinoma of the breast 0.15 mg/kg body wt/day or 6 mg/m2 body surface area/day for 5 days & repeated every 6 wk. Polycythaemia rubra vera Remission induction: 6-10 mg daily for 5-7 days, after which 2-4 mg daily is given until satisfactory disease control is achieved. Maintenance: 2-6 mg once a wk. |
|
Administration |
Should be taken on an empty stomach (Take on an empty stomach 1 hr before or 2 hr after meals. Swallow whole, do not break/crush.). |
|
Contraindications |
Lactation. |
|
Special Precautions |
Monitor blood counts; should not be given to patients who have recently received radiotherapy or other cytotoxic agents. Pregnancy. Renal impairment. Mutagenicity. Carcinogenicity. |
|
Adverse Drug Reactions |
Bone marrow depression. GI effects. Occasionally, maculopapular rashes & pruritus. Urticaria, oedema, skin rashes. Anaphylactic shock, cardiac arrest (rare). Pulmonary fibrosis, haemolytic anaemia, alopecia.
View ADR Monitoring Form |
|
Drug Interactions |
Nalidixic acid, cyclosporin.
View more drug interactions with Alkeran |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Alkeran tablet |
|
|
|
Manufacturer: |
Invida |
|
Distributor: |
Zuellig
|
|
|
|
